Results 131 to 140 of about 11,837 (160)

Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study

Antimicrobial Agents and Chemotherapy, 2023
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown.
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Amin Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Y. Alsowaida   +14 more
semanticscholar   +1 more source

Global trends of ceftazidime–avibactam resistance in gram-negative bacteria: systematic review and meta-analysis

Antimicrobial Resistance and Infection Control
The emergence of antimicrobial resistance in Gram-negative bacteria (GNB) is a major global concern. Ceftazidime–avibactam (CAZ–AVI) has been identified as a potential treatment option for complicated infections.
Yang Wang, Mohammad Sholeh, Lu Yang, Matin Zafar Shakourzadeh, Masoumeh Beig, K. Azizian   +5 more
semanticscholar   +1 more source